Lunesta eszopiclone: Additional Phase IIIb/IV data

Additional data from a 4-week, double-blind, placebo-controlled Phase IIIb/IV study in 410 patients showed that 3 mg Lunesta

Read the full 188 word article

How to gain access

Continue reading with a
two-week free trial.